Meet our Companies: Therapeutics Innovators in the PLSG Portfolio
Healthcare is changing at a rapid pace and technology is one impetus behind the evolution. Organizations like the Pittsburgh Life Sciences Greenhouse have the privilege of supporting and nurturing the innovative companies that are propelling the industry forward into a new age. In our last blog, we took a closer look at the medical device companies we’re working with. We’d now like to introduce you to some the other companies in our portfolio. The organizations in this overview come from our Therapeutics category.
What is Therapeutics?
Simply put, therapeutics deals specifically with the treatment of disease. Several of the companies in our portfolio are currently in pre-clinical and clinical stages of product development. It’s exciting to walk with them on this journey of research, development and trialing their innovative treatments. The innovative entrepreneurs behind these companies are striving to treat a wide range of diseases and disorders.
Complexa is a clinical-stage biopharmaceutical company focused on developing a new a new class of drugs to treat patients with severe and life-threatening fibrosis and inflammatory diseases. The company aims to create treatments that will prevent and repair tissue injury, as well as reverse fibrosis and inflammation.
Chemotherapy and radiation treatments may create their own collateral damage when used to treat cancer patients. Lipella Pharmaceuticals is developing products that can provide supportive care for cancer survivors with hemorrhagic cystitis. The company also has other urinary bladder conditions products in the pipeline.
Qrono Inc, enables medications, patient adherence, patient outcomes and faster time-to-market using an innovative technology to create long-acting injectable formulations.
Sharp Edge Labs
This therapeutics company is developing small molecule drugs for genetic disorders of protein trafficking. The technology Sharp Edge Labs enables the dissection of each step in the lifecycle of a protein in order to better understand the trafficking of the target as well as defects in trafficking caused by mutation.
Cognition Therapeutics (CogRX) is developing a small molecule therapeutics targeting the toxic proteins that cause cognitive decline associated with Alzheimer’s disease and related neurodegenerative diseases. Earlier this year, the company published clinical data from its Phase 1 trial of its drug Elayta in Alzheimer’s & Dementia: Translational Research & Clinical Interventions.
Knopp Biosciences seeks to discover, develop and deliver medicines to treat diseases that impose high costs on the healthcare system. Currently their research has led to an investigational compound in clinical development for immunological and hematological disorders, as well as discovery platforms directed to small molecule mediators of epilepsy and neuropathic pain.
The early-stage biotechnology company Peptilogics is developing systemic anti-infective drugs called Engineered Cationic Antibiotic Peptides (eCAPs). Current pre-clinical data indicate that eCAPS may be effective in treating drug-resistant hospital-acquired infections.
These companies represent just one category of the PLSG portfolio. In addition to these innovative therapeutics companies, we also work with organizations that are shaking things up in the area of Medical Devices, Health IT, Diagnostics, and Bio Tools. You can learn more about those companies here.